Indaptus Therapeutics, Inc.
NASDAQ:INDPBiotechnology
-$0.03 today
- Market cap
- $372.57M
- Beta
- 1.14
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.70
Volume 0.17M
Average 0.97M
INDP Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Indaptus Therapeutics, Inc.NASDAQ: INDP
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash growth accelerates
Q1 FY2026 net change in cash of $7.01M (cash outflow) rose 269.8% year over year, ahead of the -59.1% change in trailing-twelve-month net change in cash.
Context
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +269.8% holds above the trailing-twelve-month pace of -59.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 2.72M USD
- Year-over-year change
- +135.9%
- 4-year CAGR
- -48.1%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.72M | +135.9% |
| FY2024 | 2024-12-31 | (7.58M) | -302.8% |
| FY2023 | 2023-12-31 | 3.74M | +112.7% |
| FY2022 | 2022-12-31 | (29.51M) | -178.7% |
| FY2021 | 2021-12-31 | 37.49M | — |
Net Change in Cash vs competitors
How INDP compares with its peers on the latest reported figures
- INDP's LTM Mar 2026 net change in cash of $2.39M is the smallest of the 2 companies compared; the peer median is $5.68M.
- Its year-over-year change of -59.1% is the lowest of 2, against a peer median of +2241.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.68M | +2241.7% | -18.3% | — | |
| LTM Mar 2026 | $2.39M | -59.1% | — | — | |
| Peer median (excluding INDP) | $5.68M | +2241.7% | -18.3% | — | |
Competitors are the stored peer set for INDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Depreciation & Amortization | 1.4K | 1.78K | 1.28K | 735 | 0 |
| Deferred Income Tax | (5.75M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.51M | 2.96M | 2.97M | 2.31M | 1.36M |
| Change in Working Capital | (5.09M) | (1.58M) | (518.07K) | 392.26K | 3.51M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.24M) | (1.15M) | (680.52K) | 474.06K | 2.85M |
| Other Working Capital | (854.15K) | (425.59K) | 162.45K | (81.8K) | 665.3K |
| Other Non-Cash Items | 5.75M | (134.16K) | (430.99K) | 0 | 1.15M |
| Operating Cash Flow | (11.29M) | (13.08M) | (13.41M) | (12.32M) | (14.82M) |
| Capital Expenditures | (3.85K) | (172.56K) | 0 | 0 | (4) |
| Acquisitions (Net) | 451.6K | 172.56K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (29.6M) | (6.86M) | 0 | 0 |
| Sales of Investments | 0 | 13M | 24M | 0 | 0 |
| Other Investing Activities | 0 | 172.56K | 0 | 0 | 0 |
| Investing Cash Flow | 447.75K | (16.43M) | 17.14M | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 5.71M |
| Common Stock Issued | 5M | 0 | 0 | 5.51M | 11.83M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 43.34M | 0 | 0 | (762.7K) | 0 |
| Financing Cash Flow | 48.34M | 0 | 0 | 4.75M | 17.54M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.49M | (29.51M) | 3.74M | (7.58M) | 2.72M |
| Free Cash Flow | (11.29M) | (13.25M) | (13.41M) | (12.32M) | (14.82M) |
Indaptus Therapeutics, Inc.
NASDAQ:INDP
Intrinsic Alpha fair value
Locked
Current Price
$3.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.